Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: GlobeNewswire
WALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced scientific presentations at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), held February 18-21, 2026 in Stockholm, Sweden. “We are excited to share follow-up data out to 20 weeks from our Phase 1 study of SPY003, our potential best-in-class anti-IL-23 agent in development for IBD. The data showed SPY003 was well tolerated, had a differentiated PK profile supporting quarterly or twice-yearly dosing, and demonstrated targeted biological activity via a reduction in downstream cytokines. In addition, we are presenting details of our innovative SKYLINE platform trial evaluating long-acting antibodies as monotherapies and in rational combinations, as well as precl
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026 [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswire
- Hot Picks: Biotech sector draws investor attention ahead of key data [BNN Bloomberg (Canada)]BNN Bloomberg
- Spyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswire
- Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance [Yahoo! Finance]Yahoo! Finance
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/4/26 - Form 4
- 1/23/26 - Form 4
- SYRE's page on the SEC website